In this article, the authors compare and contrast the OECD Guidelines and regulations in Europe and the US with respect to intangible sharing and development among multinational enterprises.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...